Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.6952W HIGH $3.78
Volume
70.04 K
Value Traded
65.00 K
Short % Float
4.99%
-8.27%Week
+9.69%1 Month
-63%3 Month
-56.55%6 Month
-85.15%5 Year
-99.72%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
15.21 M
EPS (TTM)
-0.56
P/E Ratio
-
Ent. Value
2.59 M
Total Shares
19.67 M
Float Shares
17.22 M
Insiders
12.47%
Institutions
12.18%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
DARE Catalyst Timeline
Dated clinical, regulatory and corporate events for Dare Bioscience, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dare Bioscience, Inc.
361Total events
12Upcoming
100Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆Poster PresentationSildenafilPresentation
Phase 1 Sildenafil Cream data to be presented at SMSNA Annual Fall Scientific Meeting
healthy male adultssource ↗
●R&D DayPresentation
Management on-site for one-on-one investor meetings at H.C. Wainwright 28th Annual Global Investment Conference
▲PublicationSildenafilPresentation
Peer-reviewed publication in Sexual Medicine of Phase 1 topical Sildenafil Cream study in healthy men
systemic pharmacokinetics and safety in healthy adult mensource ↗
▲PK PD DataSildenafilClinical Data
Phase 1 topical Sildenafil Cream showed ~187-fold lower mean Cmax at 71 mg vs 50 mg oral sildenafil
systemic pharmacokinetics in healthy adult mensource ↗
▲Safety Data UpdateSildenafilClinical Data
Phase 1 study reported all 14 TEAEs mild, no serious AEs or discontinuations
safety in healthy adult mensource ↗
●R&D DayPresentation
Daré Bioscience pre-recorded presentation available on-demand for H.C. Wainwright 28th Annual Global Investment Conference
▲Preclinical PoCDARE-PTB2Preclinical
NIH funding award for preclinical development of DARE-PTB2
preterm birthsource ↗
▲PublicationSildenafilPresentation
Sildenafil Cream data published in Menopause journal
postmenopausal womensource ↗
◆Equity OfferingCorporate
Closing of registered direct offering and concurrent private placement
▲Patent GrantedDARE-HPVIP / Competition
U.S. Patent No. 12,678,439 issued covering lopinavir/ritonavir topical compositions for HPV-related cervical pathologies
HPV-related cervical pathologiessource ↗
▲Product LaunchSildenafilPost-Market
Progressing toward national dispensing and initial revenue
▲Trial InitiationDARE-HPVTrial
Initiation of Phase 2 clinical study of DARE-HPV
persistent high-risk HPV infectionsource ↗
▲Product LaunchPost-Market
Flora Sync LF5 expected to become commercially available through DARE Health Hub
vaginal microbiome balancesource ↗
◆Quarterly UpdateCorporate
Full Year 2025 Financial Results and Company Update Conference Call
▲Product LaunchPost-Market
Commercial launch of DARE to PLAY Sildenafil Cream as 503B compounded product
female sexual arousal disordersource ↗
▲Product LaunchSildenafilPost-Market
DARE to PLAY™ Sildenafil Cream available as Section 503B compounded product
female sexual arousalsource ↗
▲IND ClearanceDARE-HPVIND
FDA clearance of IND for DARE-HPV
high-risk human papillomavirus (HPV) infectionsource ↗
▲IND ClearanceDARE-HPVIND
FDA cleared IND for DARE-HPV Phase 2 study
persistent high-risk HPV infectionsource ↗
▲Product LaunchSildenafilPost-Market
Telehealth consultations for DARE to PLAY™ Sildenafil Cream now available nationwide
female sexual arousalsource ↗
◆Partnership / LicenseOvapreneCorporate
Bayer terminates license agreement for Ovaprene; rights to return to Dare
contraceptionsource ↗
▲IND ClearanceDARE-HPVIND
FDA cleared IND application for DARE-HPV
persistent high-risk HPV infectionsource ↗
▲Product LaunchDARE-HRT1Post-Market
Targeting availability as a Section 503B compounded drug next year
vasomotor symptoms of menopausesource ↗
▲Product LaunchPost-Market
Targeted availability of DARE to RESTORE vaginal probiotics
vaginal microbiome healthsource ↗
▲Product LaunchSildenafilPost-Market
DARE to PLAY Sildenafil Cream available for pre-order by prescription in select states via 503B outsourcing facility
female sexual arousalsource ↗
▲Product LaunchSildenafilPost-Market
Initial prescription fulfillment for DARE to PLAY Sildenafil Cream via 503B pathway
women's sexual healthsource ↗
◆Oral PresentationSildenafilPresentation
Webinar on DARE to PLAY difference with clinicians
female sexual arousal disordersource ↗
▲Milestone PaymentDARE-NHCCorporate
Anticipated grant installment for DARE-NHC
non-hormonal contraceptionsource ↗
◆Product LaunchSildenafilPost-Market
Targeted availability by prescription in the US as a compounded drug under Section 503B
female sexual arousal disordersource ↗
▲Product LaunchPost-Market
DARE to PLAY sildenafil cream expected to be available by prescription
female sexual arousal disordersource ↗
◆Product LaunchSildenafilPost-Market
Anticipated launch of DARE to PLAY Sildenafil Cream via 503B compounding pathway
female sexual arousal disordersource ↗
▲Milestone PaymentDARE-LARC1Corporate
Grant installment received for DARE-LARC1
long-acting contraceptionsource ↗
▲Product LaunchSildenafilPost-Market
Sildenafil Cream available via 503B compounding in Q4 2025
female sexual arousal disordersource ↗
▲Partnership / LicenseCorporate
Gates Foundation agreement for mentorship and project management support for preeclampsia research
preeclampsiasource ↗
▲DSMB ReviewOvapreneTrial
Positive interim DSMB outcome for Ovaprene Phase 3 study supports continued enrollment
contraceptionsource ↗
◆Oral PresentationPresentation
Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar
female sexual arousal disordersource ↗
▲Interim AnalysisOvapreneTrial
Positive interim safety and efficacy results from Phase 3 trial of Ovaprene
contraceptionsource ↗
●Enrollment UpdateOvapreneTrial
Approximately 115 participants ongoing or completed; target enrollment ~250
contraceptionsource ↗
▲Interim AnalysisOvapreneTrial
Positive interim data from Phase 3 trial of Ovaprene announced
contraceptionsource ↗
▲DSMB ReviewOvapreneTrial
DSMB reviewed interim safety data and recommended continuation without modification
contraceptionsource ↗
▲Milestone PaymentDARE-LARC1Corporate
Grant installment received for DARE-LARC1
long-acting contraceptionsource ↗
Past FDA Catalysts and PDUFA Decisions
How DARE actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | Sildenafil Cream, 3.6% | Phase 1 data presentation | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D27 / 100
Pipeline Score
$2M
Pipeline Value
$1M
Commercial Value
Richly Valued
Valuation Signal
6
Drugs Scored
0.2x
rNPV / MCap
Top 77%
Micro Cap(rank 508 of 660)
Percentile Rank
Dare Bioscience, Inc. faces pipeline headwinds (27/100), with $391M risk-adjusted pipeline value, led by DARE-HPV in Human Papilloma Virus (HPV) (Phase 2), but cash runway is a concern.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026) Revenue $1.4M x 1.0 = $1M
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DARE-HPV Small moleculeNCT07601074 | Human Papilloma Virus (HPV) | Phase 2 | RECRUITING | 118 | Dec 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every DARE program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Sildenafil Cream | female sexual arousal disorder | Phase 1 | 2026-10-08 | mean maximum plasma concentration: approximately 187-fold lower; systemic exposure AUC: approximately 33- to 34-fold lower; adverse events: All treatment-emergent adverse events reported in the study were mild, with no serious adverse eventsRead More | Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific MeetingRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Grossman Jessica D.Director | Grant/Award | 26,066 26,066 held | $0.00 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in DARE
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in DARE for Q2 2026. | ||||
DARE Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How DARE ranks across every disease it competes in
Competitive Position is a premium feature
See how DARE ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialDARE News
DARE▲ 0%today
Daré Bioscience to Present Phase 1 Sildenafil Cream Data at Sexual Medicine Society of North America (SMSNA) Annual Fall Scientific Meeting
Daré Bioscience announced the presentation of Phase 1 study data for its Sildenafil Cream at the SMSNA Annual Fall Scientific Meeting. The study demonstrated that the topical formulation resulted in significantly lower systemic exposure compared to oral sildenafil, with no serious adverse events reported. This data supports further development of the cream as a potential treatment for female sexual arousal disorder.
Read more →DAREDare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection
Daré Bioscience has announced the issuance of a new U.S. patent for its DARE-HPV program, which aims to be the first FDA-approved pharmacologic treatment for high-risk HPV infection. The program is currently in Phase 2 clinical trials, with topline results anticipated in 2027. Supported by substantial funding, DARE-HPV targets a significant unmet medical need in women's health.
Read more →DAREDaré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil
Daré Bioscience announced the publication of a Phase 1 study on its topical Sildenafil Cream, showing it has significantly lower systemic exposure compared to oral sildenafil. The study, published in Sexual Medicine, involved 62 healthy men and demonstrated the cream's safety and pharmacokinetics. Results indicate a promising approach for addressing sexual health concerns.
Read more →DAREDaré Bioscience Presentation for H.C. Wainwright 28th Annual Global Investment Conference Now Available On-Demand
Daré Bioscience has made its pre-recorded presentation for the H.C. Wainwright 28th Annual Global Investment Conference available for on-demand viewing. The presentation, led by CEO Sabrina Martucci Johnson, covers the company's recent developments and future direction. The conference will take place from September 14-16, 2026, in New York, where management will meet with investors.
Read more →DAREDaré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth
Daré Bioscience has received a new NIH funding award of approximately $908,000 to support the preclinical development of DARE-PTB2, an investigational program focused on preventing preterm birth. This funding is expected to last for one year, with the possibility of an additional grant of around $1.3 million in subsequent years. The initiative aims to create a novel therapeutic approach to address this critical health issue.
Read more →DAREDaré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series
Daré Bioscience, a biotech company dedicated to women's health, announced its participation in the virtual investor series titled 'Why Now'. The company aims to bridge the gap between scientific advancements and practical solutions for women's health. A video webcast of the event is now available for interested viewers.
Read more →DARE▼ -8.5%on this newsshared move
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in Menopause - The Journal of The Menopause Society
Daré Bioscience's clinical study on its 3.6% topical sildenafil cream showed positive results, demonstrating good tolerance among postmenopausal women with minimal systemic exposure. The company is actively working to advance this formulation through the FDA's 505(b)(2) regulatory pathway, indicating progress in its development.
Read more →DAREDaré Bioscience CEO Outlines Commercial Transformation, Pipeline Momentum and Potential Key Catalysts in Virtual Investor CEO Connect Segment
Sabrina Martucci Johnson, CEO of Daré Bioscience, shared insights on the company's transition to a commercial stage and the potential for revenue growth. She emphasized the positive interim results from the Phase 3 trial of Ovaprene and outlined key catalysts that could enhance the company's value in the next 12-18 months.
Read more →DARE▼ -5.2%on this news
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
Sabrina Martucci Johnson, CEO of Daré Bioscience, has been named to Forbes' 2026 '50 Over 50: Innovation' list. This recognition highlights her leadership as the company advances its multi-product strategy in women's health, focusing on commercialization and clinical development. Daré Bioscience aims to introduce first-in-category innovations.
Read more →DARE▼ -35.4%on this newsshared move
Daré Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Daré Bioscience has announced a registered direct offering of 4,379,581 shares at $1.37 each, aiming to raise $6 million. The offering is set to close around August 17, 2026, subject to customary conditions. Additionally, the company will issue Series A and B warrants, pending stockholder approval. This move supports Daré's mission in women's health.
Read more →DARE▼ -32.1%on this newsshared move
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances
Daré Bioscience has reported its second quarter results for 2026, highlighting the launch of Flora Sync LF5™, which started generating revenue in July. The company is also advancing its DARE to PLAY™ Sildenafil Cream, with expectations for national dispensing and initial revenue in the third quarter of 2026. Prescriptions and preorders for the cream are already being accepted.
Read more →DAREDaré Bioscience to Host Second Quarter 2026 Financial Results and Company Update Conference Call and Webcast on August 13, 2026
Daré Bioscience, Inc. will host a conference call on August 13, 2026, to discuss its financial results for Q2 2026 and provide a company update. The call will be accessible via phone and webcast, with registration recommended prior to the event. The company emphasizes its commitment to women's health through innovative solutions.
Read more →DARE▼ -10.2%on this news
Daré Bioscience Expands Access Options for DARE to PLAY™ and Specialized Menopause Care Through Strategic Collaboration with MyMenopauseRx
Daré Bioscience has announced a strategic collaboration with MyMenopauseRx to enhance access to its DARE to PLAY™ menopause telehealth option. This partnership aims to expand Daré's commercial reach and strengthen consumer engagement within the women's health sector. The initiative is part of Daré's broader strategy to create a trusted ecosystem for women's health products and services.
Read more →DARE▼ -6.7%on this news
Press Release: Daré Bioscience Launches Nationwide Virtual Bus Tour Webinar Series to Showcase Commercial Strategy and Growth Opportunities
Daré Bioscience has announced the launch of its 'Across the U.S.' Virtual Bus Tour Webinar Series aimed at engaging investors. The series will feature presentations from CEO Sabrina Martucci Johnson, discussions on the company's women's health portfolio, and updates on business initiatives. Investors can register for multiple regional events, with replays available for later viewing.
Read more →DAREPress Release: Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Daré Bioscience will participate in a Virtual Investor Closing Bell event on July 14, 2026. CEO Sabrina Martucci Johnson will discuss the company's recent product launch, strategic growth plans, and capital allocation approach. The event will also include a live Q&A session for audience engagement. A webcast will be available for those unable to attend live.
Read more →DAREDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event
Daré Bioscience's CEO, Sabrina Martucci Johnson, will participate in a virtual investor event on July 14, 2026. The event aims to enhance engagement with investors and showcase the company's commitment to women's health. The live video webcast will begin at 4:00 PM ET.
Read more →DAREPress Release: Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform
Daré Bioscience has launched Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance and enhancing vaginal comfort. This product represents the company's first direct-to-consumer offering, marking a significant shift towards revenue generation. Flora Sync LF5 is available without a prescription and is backed by clinical research demonstrating its effectiveness.
Read more →DAREPress Release: Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment
Daré Bioscience announced the upcoming launch of Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance. CEO Sabrina Martucci Johnson highlighted its significance as the company's first consumer health product, which is expected to generate direct revenue. The product aligns with Daré's mission to address women's health needs through innovative solutions.
Read more →DAREPress Release: Daré Bioscience to Showcase Leadership in Women’s Health Innovation at BIO International Convention 2026
Daré Bioscience will participate in the BIO International Convention 2026, showcasing its commitment to women's health innovation. CEO Sabrina Martucci Johnson will deliver multiple presentations, discussing the company's corporate strategy and addressing gaps in women's healthcare. The event serves as a platform for collaboration with industry leaders and investors.
Read more →DAREPress Release: Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
Daré Bioscience announced the upcoming launch of Flora Sync LF5, a vaginal probiotic capsule aimed at restoring microbiome balance and enhancing vaginal comfort. This launch signifies a pivotal transition for the company as it prepares to generate its first direct consumer product revenue. Flora Sync LF5 is designed specifically for vaginal health and will be available without a prescription, priced at $49 per box.
Read more →About Dare Bioscience, Inc.
Headquarters3655 NOBEL DRIVE, SAN DIEGO, CA, 92122
BIOPHARMAWATCH ELITE PLUS
Trade the next DARE catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime